Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Olaparib in Recurrent or Persistent EOC
NCT02485990Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2016
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of tremelimumab in epithelial ovarian carcinoma (EOC), fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2016; status: terminated.
02
Drugs
tremelimumab
03
Conditions
epithelial ovarian carcinoma (EOC)fallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02485990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485990.